The fact that reduced median survival time in the mice with FcγR blockade was observed only for TG-VHS treatment supports our proposed working model of a role of VEGFA co-phagocytosis induced by the HER2-VEGFA BsAb via ADCP of HER2-overexpressing cancer cells in leading to enhanced antitumor activity (Figure 3C and Figure 5C). The gene discussed is FCGR2A; the disease is cancer.